Scientific Publications


Cyclo Therapeutics Scientific Presentation

          December, 2023

Intravenous Trappsol® Cyclo ™ in patients with Niemann Pick Disease type C1: Updates on the Results from Phase I and Phase I/II studies and the international Phase III pivotal Transport NPC trial

          NP Association of China, Patient Group Meeting, July 16, 2023    
          Authors: Andreas Brecht, PhD – Director Medical Affairs Europe Cyclo Therapeutics


Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial

Authors: Reena Sharmaa / Caroline Hastings / Orna Staretz-Chachamc / Julian Raimand / Martin Paucar / Ronen Spiegel /
Bryan Murray / Bryan Hurst / Benny Liu / Lise Kjems / Sharon Hrynkow


TransportNPC: A Phase 3 Global Trial of Trappsol® Cyclo™ Administered Intravenously to Patients with Niemann-Pick Disease Type C1 (NPC1)

          Authors: Joseph Mejia, MD / Lise Kjems, PhD, MD / Rebecca Fine / Caroline Hastings, MD





Top Line Results of Phase I Intravenous Trial for NPC

    • NNPDF Presentation
    • Caroline Hasting, MD
    • Jul 9, 2020

Trappsol® Cyclo™ is not currently approved for any indication.

Third-party websites are provided for convenience only. Cyclo Therapeutics, Inc. does not approve of, or endorse any of the content. Cyclo Therapeutics, Inc. does not maintain, control or monitor the content of third-party websites in any way.